ADVERTISING COMMUNICATION AS OF 28 MARCH 2024



EDR FUND HEALTHCARE A-USD

EDR FUND HEALTHCARE A-USD

GLOBAL EQUITIES - THEMATIC MANAGEMENT SICAV



US AND INTERNATIONAL EQUITY

(a) MORNINGSTAR RANKING ™ ★★★

FUND SIZE: USD 595.91 mil.

Restricted registration / Qualified investors

Lower risk Higher risk

Potentially lower return Potentially higher return

6

7

The risk indicator SRI rates this fund on a scale of 1 to 7. This indicator is used to assess the level of risk of this product in comparison to other funds and a category 1 rating does not mean that the investment is risk free. In addition, it indicates the likelihood that this product will incur losses in the event of market movements or our inability to pay you. This indicator assumes that you hold the product until the end of the recommended holding period of this fund. The actual risk may be very different if you choose to exit before the end of the recommended holding period of this Fund.

Fund characteristics

Legal status

All investors

Sub-fund launch date: 03/07/2015

Recommended investment period: 5 years

Fund domicile: Luxembourg
Administrative Information

Management Company : Edmond de Rothschild Asset Management (Luxembourg)

Management company by delegation: Edmond de

Rothschild Asset Management (France)

 $\textbf{Valuation:} \mathsf{Daily}$

Administration : Edmond de Rothschild Asset Management (Luxembourg)

Decimalised: 3 decimals

Depositary: Edmond De Rothschild (Europe)
Initial minimum subscription: 1 Share
Subscription & Redemption conditions:

Daily before 12.30 pm C.E.T. on day's net asset value

Management Subscription/Redemption fees

Actual management fees: 1,7% Performance fees: yes Maximum entry fees: 3% Maximum exit fees: no Share characteristics

 Net asset value (USD):
 310.19

 Class creation date:
 03/07/2015^(o)

 ISIN code:
 LU1160358047

 Bloomberg code:
 EDRGHAU LX

 Lipper code:
 68320263

 Telekurs code:
 26427887

 Distribution:
 Accumulation

 Latest coupon:

Fund Managers

Adeline SALAT-BAROUX, Sébastien Malafosse

Risks

The main risks of this UCITS are:

- Equity risk
- Interest rate risk
- Currency risk
- Equity Risks associated with small and mid caps
- Discretionary management risk

GENERAL INFORMATION


Investment objective and SRI approach

: AT BE CH DE ES FR GB IT LU PT

The objective of the Product is to outperform its benchmark by investing in companies operating in the healthcare sector, that meet environmental, social and governance (ESG) criteria.

PERFORMANCES

: CL SG



Benchmark (Index): MSCI AC World Health Care (NR) (USD)

The benchmark has changed since this UCI was created. The performance data for the benchmark has been chain-linked in order to take the successive changes into account.

Past performances and volatility are not a reliable indicator of future performance and volatility. They may vary over time. The performances shown do not take into account the fees and expenses borne at the time of issue and redemption of units but include ongoing charges, brokerage fees and any performance fees taken.

(D) once the legal nature of this UCITS is amended, with no impact on the purpose of the fund, and once the performance history is preserved, the launch date of the fund may fall after the start date of the performance history.



Rolling performance as of 28 March 2024 (Net of fees) Cumulative

	1 month	YTD	1 year	3 years	5 years	10 years	Since inception	Since inception
Class (A)	3.15	1.38	3.63	6.93	38.19	74.74	210.19	8.97
Index	2.23	7.05	12.82	21.75	59.54	133.13	327.61	11.66

Annualised

STATISTICS & PERFORMANCE ANALYSIS

0.93


Statistics (Rolling periods))					
		weeks (. perf.)	3 yea (month. p			5 years nth. perf.)
	Class	Index	Class	Index	Class	Index
Volatility (%)	12.79	11.62	13.87	13.92	14.24	14.37
Tracking error (%)	4.74		4.64		4.58	
Sharpe ratio	-0.03	0.76	-0.03	0.30	0.33	0.54
Information ratio	-1.93		-0.98		-0.68	
Alpha	-0.17		-0.33		-0.19	
Beta	1.02		0.94		0.94	
R2	0.86		0.89		0.90	

0.94


Performance analysis Since 28/01/2011 (month. perf.) % of positive performances 60.51 Minimum return (%) -10.33 Maximum return (%) 12.64 493 day(s) Payback period

PORTFOLIO ANALYSIS

Correlation



0.95



Financial	data (weighte	ed averages)			
PER 2024	PER 2025	EPS var. 2024/2025	PCF 2024	PBV 2024	Yield 2024
26.58	20.68	11.88	17.97	3.15	1.73

Top holdings

10 Main holdings (Number of holdings: 40)

	Sector	Expo (%NA)
CVS HEALTH CORP	Health Care Providers & Services	5.03
PFIZER INC	Pharmaceuticals	4.95
UCB SA	Pharmaceuticals	4.37
NOVARTIS AG	Pharmaceuticals	3.86
NOVO NORDISK A/S	Pharmaceuticals	3.84
ELI LILLY & CO	Pharmaceuticals	3.81
ASTRAZENECA PLC	Pharmaceuticals	3.69
SIEMENS HEALTHINEERS AG	Health Care Equipment & Supplies	3.58
BAXTER INTERNATIONAL INC	Health Care Equipment & Supplies	3.56
UNITEDHEALTH GROUP INC	Health Care Providers & Services	3.29
Total		39.98

Main movements of the month

NAW	positions
1464	positions
	•

No new position

Strengthened positions DENTSPLY SIRONA INC

PACIFIC BIOSCIENCES OF CA

Sold positions

CENTENE CORP

Reduced positions

CVS HEALTH CORP ABBOTT LABORATORIES

RADNET INC

PERFORMANCE CONTRIBUTION

Top 5 positive performers (from 29/02/2024 to 28/03/2024)		
	Av. weight (%)	Contribution (%)
CVS HEALTH CORP	5.54	0.41
EXACT SCIENCES CORP	2.06	0.40
LONZA GROUP AG	2.68	0.38
UCB SA	4.42	0.33
BROOKDALE SENIOR LIVING INC	2.07	0.31

Top 5 negative performers

(from 29/02/2024 to 28/03/2024) Av. weight (%) Contribution (%) PACIFIC BIOSCIENCES OF CALIFORNIA INC 1.07 -0.46 WUXI BIOLOGICS CAYMAN INC 0.88 -0.26 BEIGENE LTD 2.54 -0.14 ABBOTT LABORATORIES 2.02 -0.12 **NOVARTIS AG** 3.92 -0.08

Data sources: Edmond de Rothschild Asset Management - Accounting Data - External Data Providers - MSCI ESG Rating



contact-am@edr.com



http://funds.edram.com

In this section, EdRAM presents a series of sustainability indicators related to the fund and benchmark holdings.



Benchmark (Index): MSCI AC World Health Care (NR) (USD)

Engagement Formalized approach aimed at positively influencing the consideration of ESG issues by companies.



ESG rating: source EdRAM/MSCI; translation of the ESG score into an ESG rating on a scale from AAA (best) to C (worst).



Source MSCl; red: very severe controversy(ies); orange: severe controversy(ies); yellow: significant controversy(ies), green: no major controversy(ies)

Climate alignment (°C)	
Fund	2.88
Benchmark	2.93

Climate alignment (°C): the global warming trajectory (°C) of each company in the portfolio based on its carbon footprint (scopes 1, 2 and 3*), the efforts undertaken to reduce it and the strategy announced to contribute to the fight against global warming. The trajectory is derived from the individual company's performance compared to a warming trajectory of the global economy of 1.5°C. The trajectories of the companies in the portfolio are then aggregated. Ratios as of 29/02/2024


GHG emissions intensity (scopes 1 and 2	2)	Coverage
Fund	2.04	99.26%
Benchmark	4.77	99.32%
Source: Carbon4 Finance; GHG emissions intensity so million Euros invested. Ratios as of 29/02/2024	opes 1 and 2* (retr	eated) tons CO2 per

GHG emissions intensity (scopes 1, 2 and 3)		Coverage
Fund	23.75	99.26%
Benchmark	45.81	99.32%

Source : Carbon4 Finance ; GHG emissions intensity scopes 1,2 and 3^* (retreated) tons CO2 per million Euros invested. Ratios as of 29/02/2024

ESG Rating ввв AA BB В **CCC & Below** Fund Α **BBB** Benchmark A BB R **CCC & Below** 58.83 58.46 99.37% 99.65% Fund Fund Benchmark **ESG Score** Coverage

ESG score: source EdRAM/MSCl; ESG score on a scale from 0 (worst score) to 100 (best score). ESG rating: source EdRAM/MSCl; translation of the ESG score into an ESG rating on a scale from AAA (best) to C (worst).



Source: EdRAM/MSCI; E, S and G scores on a scale from 0 (worst score) to 100 (best score)

	ESG Score	Expo (%NA)
ELEVANCE HEALTH INC	76.5	2.58
WUXI BIOLOGICS CAYMAN INC	72.0	0.77
UNITEDHEALTH GROUP INC	71.5	3.29
EVOTEC SE	70.0	1.23
IQVIA HOLDINGS INC	69.0	3.09
Total		10.97

ESG score: source EdRAM/MSCI; ESG score on a scale from 0 (worst score) to 100 (best score).

Top GHG emissions intensity (scopes 1, 2 and 3)

5 Worst performers

	GHG emissions intensity	Expo (%NA)
CVS HEALTH CORP	218.8	5.03
UNITEDHEALTH GROUP INC	96.6	3.29
ELEVANCE HEALTH INC	96.5	2.58
BIONTECH SE	86.8	0.60
SHANDONG WEIGAO GROUP MEDICAL POLYMELTD	R CO 60.3	0.85
Total		12.35

Source: Carbon4 Finance; GHG emissions intensity scopes 1,2 and 3* (retreated) tons CO2 per million Euros invested. Ratios as of 29/02/2024

Top GHG emissions intensity savings (scopes 1, 2 and 3)

5 Best performers

GHG emi	issions intensity savings	Expo (%NA)
CVS HEALTH CORP	-21.8	5.03
ELEVANCE HEALTH INC	-16.5	2.58
UNITEDHEALTH GROUP INC	-16.5	3.29
LONZA GROUP AG	-4.2	2.92
PACIFIC BIOSCIENCES OF CALIFORNIA INC	-1.0	1.04
Total		14.86

Source: Carbon4 Finance; GHG emissions intensity savings (retreated) tons CO2 per million Euros invested; emissions saved being the sum of avoided emissions** and reduced emissions***. Emissions savings are "virtual" emissions that would exist unless the company had actively tried to decrease them. They are expressed as "negative emissions"; the lower the figure, the higher the emissions intensity savings. Ratios as of 29/02/2024

*Scope 1: direct emissions from resources owned and controlled by the company / Scope 2: indirect emissions from the production of energy purchased / Scope 3: all indirect emissions that are related to the company's operations and not included in Scope 2 **Avoided emissions are the difference between the GHG emissions intensity and a reference scenario. ***Reduced emissions are the emissions resulting from the entity's own efficiency improvements, calculated as the company's current GHG emissions intensity compared to the same metrics 5 years ago.

IN THIS SECTION, EDRAM PRESENTS A SERIES OF SUSTAINABILITY INDICATORS RELATED TO THE FUND AND BENCHMARK HOLDINGS.



Source: MSCI/EdRAM; Exposure to the 17 United Nations Sustainable Development Goals. Net activation (sum of positive and negative activations) of securities as a % of assets of the fund or index. Exposure is defined as the opportunity for each company to make a positive contribution to the achievement of the SDGs, through the products and services they offer and through their business practices;

Biodiversity data



Biodiversity impact intensity (in MSAppb* per €bn invested)

Fund	24.64
Benchmark	35.74

Source Carbon4 Finance: MSAppb* (mean species abundance, parts per billion euros invested or revenue) expresses the average relative abundance of original species compared to their abundance in pristine ecosystems. This indicator is the result of mathematical transformations, with the MSA scaled down. Km2 with 1 MSA.km2 lost, equivalent to the total concrete development of 1 km² of pristine natural area.



Estimated percentage of operations in business sectors with a high potential for disturbing land and marine areas

Fund	0.00
Benchmark	0.23
	0.25
Source: MSCI, % of assets of the fund or index	



Estimated percentage of operations located in areas with highly fragile ecosystems

ruliu	57.19
Benchmark	61.06

Source: MSCI, % of assets of the fund or index

PRODUCT DISCLAIMER

This document was issued on 28/03/2024 by EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) global distributor

47, rue du Faubourg Saint-Honoré

75401 Paris Cedex 08

A limited company with executive and supervisory boards and capital of 11.033.769 Euro

AME approval number GP 04000015

332 652 536 R.C.S. Paris

http://www.edram.fr

EdR Fund Healthcare is a sub-fund of the Luxembourg-registered SICAV approved by the CSSF and authorised for marketing in Austria, Belgium, Switzerland, Germany, Spain, France, United Kingdom, Italy, Luxembourg and Portugal

This document is not contractual and is to be used for information purposes only. Reproducing or using the contents of this document without the consent of the Edmond de Rothschild Group is strictly prohibited.

The information contained in this document should not be regarded as a transaction offer or solicitation in a jurisdiction in which such offer or solicitation is unlawful or in which the person making such offer or solicitation is not authorised to do so. This document does not constitute and should not be construed as investment advice, tax or legal advice, or a recommendation to buy, sell or continue to hold an investment.

EdRAM may not be held responsible for an investment or divestment decision made on the basis of this information.

This document has not been reviewed or approved by a regulator from any jurisdiction. The regulations relating to the method of marketing a UCI vary depending on the country. The UCI presented here may not be authorised for marketing in your country of residence. In case of doubt regarding your ability to invest in a UCI, please contact your regular advisor.

This document is not intended for citizens or residents of the United States of America or "US Persons" as that term is defined in "Regulation S" of the US Securities Act of 1933. No investment products presented here are permitted for sale under the Securities Act of 1933 or any other regulation applicable in the United States. Accordingly, no investment product may be offered or sold directly or indirectly in the United States of America to residents and citizens of the United States of America or to "US Persons".

The figures, comments, forecasts, and other elements in this presentation are a reflection of EdRAM's impression of the markets and their changes, taking both the economic context and currently available information into consideration. They may no longer be relevant on the day that the investor becomes aware of them. Consequently, EdRAM cannot be held responsible for the quality or exactness of the information and economic data provided by third parties.

Information on securities should not be construed as an opinion of Edmond de Rothschild Asset Management (France) concerning the foreseeable evolution of said securities and, if applicable, the foreseeable evolution of the price of financial instruments issued by them. This information should not be considered a recommendation to buy or sell these securities. The composition of the portfolio may change over time.

All investments are subject to specific risks. Investors are advised to ensure that any investments are appropriate to their individual circumstances, seeking independent advice if necessary. In addition, they must read the key information document (KID) and/or any other documents required by local regulations issued before any investment is made, and available at www.edmond-de-rothschild.com under the heading "Fund Center", or free of charge on request.

Tax treatment depends on the individual situation of each client and may be modified at a later date.

"Edmond de Rothschild Asset Management" or "EdRAM" is the trading name of the asset management entities of the Edmond de Rothschild Group.

A detailed description of the target investor provisions and the risks specific to UCIs can be found in the prospectus of this UCI authorized by FINMA for the offering to non-qualified investors in Switzerland. The status, the prospectus, the key investor information document as well as the annual and half-yearly reports are available on request from Edmond de Rothschild Asset Management (France), its distributors and/or representatives and/or contacts, a list of whom is available on the following website (http://funds.edram.com), so that investors can assess their risk and form their own opinion independently of any entity of the Edmond de Rothschild Group, by seeking, if necessary, the advice of advisors specialized in these questions, to ensure in particular the appropriateness of this investment to their financial situation, to their experience, and to their investment objectives.

The information contained in this document relating to this LICL is not intended to replace the information in the prospectus, or the semi-annual and annual reports. Investors are required to read such additional documentation before making any investment decision.

18, rue de Hesse

1204 Genève

Switzerland

EdR Fund Healthcare A-USD is registered with the CNMV under number 229

(a) Morningstar Ranking as of 29/02/2024 in the category Sector Equity Healthcare.

Switzerland (Legal Representative and Paying agent): Edmond de Rothschild (Suisse) S.A.

The Morningstar ratings are not market rankings and are not to be considered as recommendations to buy, sell, or hold units or shares in UCIs managed by Edmond de Rothschild Asset Management (France). Reference to a ranking or a price for this UCI is not a guide for future rankings or prices of these UCIs or of the investment manager.

Source - Morningstar, Inc. All rights reserved. The information contained in this document: (1) is the proprietary material of Morningstar and/or its information providers; (2) may not be reproduced or redistributed; (3) is presented without guarantee as to its accuracy, completeness or correctness. Neither Morningstar nor its information providers may be held liable for any damage or loss resulting from the use of this data. Past performance is no guarantee of future results.

Each stock is awarded an ESG rating within Edmond de Rothschild Asset Management (France). To reach an ESG rating, the investment team conducts in-depth fundamental analysis which involves meeting the company's executive management. The team uses quantitative and qualitative estimations sourced from companies, extra-financial rating agencies and brokers. Each stock is rated according to a 7-point scale from CCC to AAA. Only the best ratings - AAA, AA and A - are eligible for the portfolio. Ratings are revised regularly.

GLOSSARY

The VOLATILITY of a security is the difference between performance and average performance and therefore makes it possible to gauge the consistency of performance obtained. It comprises a measure of risk. If this is zero, the individual performances are identical. The higher it is, the greater the difference between individual performances.

The TRACKING ERROR shows the volatility of a fund's relative performance against that of its benchmark. It shows the difference between performances and their average and so makes it possible to gauge the consistency of relative performance. The lower the tracking error, the closer the fund's performance is to that of its benchmark.

The ALPHA corresponds to the fund's average performance. More specifically, it measures the fund managers' added value while cancelling out market influence, which cannot be controlled. This measure is expressed as a percentage.

The SHARPE RATIO shows the fund's outperformance against a zero-risk interest rate, adjusted for fund volatility

Other definitions and methodologies are available at www.edmond-de-rothschild.com under the "Fund Center" tab in the fund's downloadable factsheet documentation.